Citation Report
List of articles citing

Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance

DOI: 10.1016/j.stem.2013.12.016
Cell Stem Cell, 2014, 14, 329-41.

#	Paper	IF	Citations
161	Cancer stem cells as a target population for drug discovery. **2014**, 6, 1567-85		7
160	Genetically modeled mice with mutations in mitochondrial metabolic enzymes for the study of cancer. *Frontiers in Oncology*, **2014**, 4, 200	5.3	14
159	Potential mitochondrial isocitrate dehydrogenase R140Q mutant inhibitor from traditional Chinese medicine against cancers. **2014**, 2014, 364625		5
158	IDH mutations in liver cell plasticity and biliary cancer. **2014**, 13, 3176-82		23
157	Pre-leukemic evolution of hematopoietic stem cells: the importance of early mutations in leukemogenesis. *Leukemia*, **2014**, 28, 2276-82	10.7	86
156	Epigenetics in the hematologic malignancies. **2014**, 99, 1772-83		48
155	Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C > T have a prognostic value in acute myeloid leukemia. **2014**, 2, 18		22
154	Metabolic requirements for the maintenance of self-renewing stem cells. **2014**, 15, 243-56		646
153	Development and classes of epigenetic drugs for cancer. **2014**, 455, 58-69		65
152	Connections between TET proteins and aberrant DNA modification in cancer. **2014**, 30, 464-74		177
151	Somatic alterations and dysregulation of epigenetic modifiers in cancers. **2014**, 455, 24-34		25
150	The role of mutation of metabolism-related genes in genomic hypermethylation. **2014**, 455, 16-23		20
149	Neue Entwicklungen in der Therapie maligner hämatologischer Erkrankungen. **2014**, 29, 316-323		
148	The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation. **2014**, 1846, 326-41		93
147	The molecular basis of myeloid malignancies. **2014**, 90, 389-404		13
146	Functions of idh1 and its mutation in the regulation of developmental hematopoiesis in zebrafish. *Blood*, **2015**, 125, 2974-84	2.2	14
145	Genetic dissection of leukemia-associated IDH1 and IDH2 mutants and D-2-hydroxyglutarate in Drosophila. *Blood*, **2015**, 125, 336-45	2.2	25

144	Fish provide ID(H)eas on targeting leukemia. *Blood*, **2015**, 125, 2880-2	2.2	0
143	Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics. **2015**, 170, 305-22		28
142	Functions of TET Proteins in Hematopoietic Transformation. **2015**, 38, 925-35		15
141	Mutant IDH1 Dysregulates the Differentiation of Mesenchymal Stem Cells in Association with Gene-Specific Histone Modifications to Cartilage- and Bone-Related Genes. **2015**, 10, e0131998		43
140	Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms. *Leukemia*, **2015**, 29, 2134-42	10.7	57
139	Mitochondrial dependency in progression of acute myeloid leukemia. **2015**, 21, 41-8		32
138	Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia. **2015**, 7, 291ra96		37
137	Enigmas of IDH mutations in hematology/oncology. **2015**, 43, 685-97		21
136	Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond. **2015**, 43, 673-84		74
135	Loss of c-Cbl E3 ubiquitin ligase activity enhances the development of myeloid leukemia in FLT3-ITD mutant mice. **2015**, 43, 191-206.e1		8
134	Mathematical analysis predicts imbalanced IDH1/2 expression associates with 2-HG-inactivating Ɛoxygenation pathway in colorectal cancer. **2015**, 46, 1181-91		12
133	IDH2 and NPM1 Mutations Cooperate to Activate Hoxa9/Meis1 and Hypoxia Pathways in Acute Myeloid Leukemia. *Cancer Research*, **2015**, 75, 2005-16	10.1	35
132	Clinical and molecular genetic characterization of myelofibrosis. **2015**, 22, 177-83		12
131	Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia. **2015**, 27, 502-15		145
130	New IDH1 mutant inhibitors for treatment of acute myeloid leukemia. **2015**, 11, 878-86		117
129	Dysregulated metabolism contributes to oncogenesis. **2015**, 35 Suppl, S129-S150		189
128	Aldehyde dehydrogenases and cancer stem cells. **2015**, 369, 50-7		118
127	TET proteins and 5-methylcytosine oxidation in hematological cancers. **2015**, 263, 6-21		134

126	IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives. **2016**, 7, 171-80		118
125	Oxidative stress and hypoxia in normal and leukemic stem cells. **2016**, 44, 540-60		61
124	Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate. *Leukemia*, **2016**, 30, 1708-15	10.7	31
123	Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure. *Blood*, **2016**, 128, 1246-59	2.2	91
122	MicroRNAs in Control of Stem Cells in Normal and Malignant Hematopoiesis. **2016**, 2, 183-196		15
121	Mutant IDH: a targetable driver of leukemic phenotypes linking metabolism, epigenetics and transcriptional regulation. **2016**, 8, 945-57		17
120	Oncometabolite D-2-Hydroxyglurate Directly Induces Epithelial-Mesenchymal Transition and is Associated with Distant Metastasis in Colorectal Cancer. *Scientific Reports*, **2016**, 6, 36289	4.9	64
119	Combination of RNA- and exome sequencing: Increasing specificity for identification of somatic point mutations and indels in acute leukaemia. **2016**, 51, 27-31		3
118	Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia. **2016**, 101, 20-5		40
117	The oncometabolite R-2-hydroxyglutarate activates NF-B-dependent tumor-promoting stromal niche for acute myeloid leukemia cells. *Scientific Reports*, **2016**, 6, 32428	4.9	34
116	Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility. **2016**, 9, 447-69		9
115	IDH mutations in cancer and progress toward development of targeted therapeutics. **2016**, 27, 599-608		269
114	Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer. **2016**, 22, 1837-42		120
113	Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia. *Journal of Experimental Medicine*, **2016**, 213, 483-97	16.6	54
112	Epigenetics - A Different Way of Looking at Genetics. *Epigenetics and Human Health*, **2016**,		
111	Novel working hypothesis for pathogenesis of hematological malignancies: combination of mutations-induced cellular phenotypes determines the disease (cMIP-DD). **2016**, 159, 17-25		4
110	Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias. *Leukemia*, **2017**, 31, 151-158	10.7	40
109	A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML. *Leukemia*, **2017**, 31, 1466-1470	10.7	19

108	Understanding the Intersections between Metabolism and Cancer Biology. **2017**, 168, 657-669		971
107	L-2-Hydroxyglutarate production arises from noncanonical enzyme function at acidic pH. **2017**, 13, 494-500		129
106	AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic Mutations. **2017**, 7, 478-493		248
105	Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in - and -Mutant Acute Myeloid Leukemia. **2017**, 7, 494-505		68
104	Epigenetics in normal and malignant hematopoiesis: An overview and update 2017. **2017**, 108, 553-562		35
103	TET family dioxygenases and DNA demethylation in stem cells and cancers. **2017**, 49, e323		82
102	Enasidenib in mutant relapsed or refractory acute myeloid leukemia. *Blood*, **2017**, 130, 722-731	2.2	831
101	Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. *Blood*, **2017**, 130, 732-741	2.2	230
100	RNA-Guided CRISPR-Cas9 System-Mediated Engineering of Acute Myeloid Leukemia Mutations. **2017**, 6, 243-248		10
99	The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia. **2017**, 96, 1983-1991		51
98	Oncogenic Activities of IDH1/2 Mutations: From Epigenetics to Cellular Signaling. **2017**, 27, 738-752		67
97	Importance of R-CF□□O Tetrel Bonding Interactions in Biological Systems. **2017**, 121, 5371-5376		52
96	Tumor-initiating cells of breast and prostate origin show alterations in the expression of genes related to iron metabolism. *Oncotarget*, **2017**, 8, 6376-6398	3.3	48
95	Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors. **2018**, 24, 1705-1715		53
94	IDH1R132H Promotes Malignant Transformation of Benign Prostatic Epithelium by Dysregulating MicroRNAs: Involvement of IGF1R-AKT/STAT3 Signaling Pathway. **2018**, 20, 207-217		9
93	A non-cell-autonomous role for Pml in the maintenance of leukemia from the niche. **2018**, 9, 66		14
92	The role of IDH mutations in acute myeloid leukemia. **2018**, 14, 979-993		57
91	Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes. **2018**, 144, 1037-1047		14

90	Impact of DNA methylation programming on normal and pre-leukemic hematopoiesis. **2018**, 51, 89-100		14
89	Differentiation therapy revisited. **2018**, 18, 117-127		190
88	Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia. **2018**, 14, 23-40		30
87	Characterization of IDH1 p.R132H Mutant Clones Using Mutation-specific Antibody in Myeloid Neoplasms. **2018**, 42, 569-577		5
86	Epigenetics in myelodysplastic syndromes. **2018**, 51, 170-179		33
85	Enasidenib for the treatment of acute myeloid leukemia. **2018**, 11, 755-760		25
84	Mitochondria in cancer metabolism, an organelle whose time has come?. **2018**, 1870, 96-102		22
83	Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations. **2018**, 559, 125-129		150
82	Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib. **2018**, 24, 1167-1177		102
81	Metabolic traits of cancer stem cells. **2018**, 11,		51
80	Evolving Treatment Strategies for Elderly Leukemia Patients with IDH Mutations. *Cancers*, **2018**, 10,	6.6	18
79	Loss-of-Function Mutations Derepress ASH1L to Increase Gene Expression and Promote Leukemogenesis. *Cancer Research*, **2018**, 78, 3510-3521	10.1	17
78	Isocitrate dehydrogenase 1-mutated human gliomas depend on lactate and glutamate to alleviate metabolic stress. **2019**, 33, 557-571		23
77	Which are the most promising targets for minimal residual disease-directed therapy in acute myeloid leukemia prior to allogeneic stem cell transplant?. **2019**, 104, 1521-1531		13
76	Exploiting metabolic vulnerabilities for personalized therapy in acute myeloid leukemia. **2019**, 17, 57		18
75	Isocitrate dehydrogenase inhibitors in acute myeloid leukemia. **2019**, 7, 22		47
74	The functional mechanisms of mutations in myelodysplastic syndrome. *Leukemia*, **2019**, 33, 2779-2794	10.7	11
73	The Interplay Between the Genetic and Immune Landscapes of AML: Mechanisms and Implications for Risk Stratification and Therapy. *Frontiers in Oncology*, **2019**, 9, 1162	5.3	11

72	Targeting Metabolic Reprogramming in Acute Myeloid Leukemia. **2019**, 8,		24
71	Characterization of cancer-associated IDH2 mutations that differ in tumorigenicity, chemosensitivity and 2-hydroxyglutarate production. *Oncotarget*, **2019**, 10, 2675-2692	3.3	7
70	Warburg and Krebs and related effects in cancer. **2019**, 21, e4		15
69	Enasidenib in acute myeloid leukemia: clinical development and perspectives on treatment. **2019**, 11, 8073-8080		8
68	Control of the Antitumor Immune Response by Cancer Metabolism. **2019**, 8,		27
67	Cancer-associated mutation and beyond: The emerging biology of isocitrate dehydrogenases in human disease. **2019**, 5, eaaw4543		60
66	-mutated cancers are sensitive to the green tea polyphenol epigallocatechin-3-gallate. *Cancer & Metabolism*, **2019**, 7, 4	5.4	10
65	Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy. **2019**, 29, 446-459		20
64	GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations. *Leukemia*, **2019**, 33, 1827-1832	10.7	8
63	Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers. *Scientific Reports*, **2019**, 9, 16830	4.9	15
62	Molecular mechanisms for stemness maintenance of acute myeloid leukemia stem cells.. **2019**, 1, 77-83		2
61	Acute myeloid leukemia with isolated del(5q) is associated with IDH1/IDH2 mutations and better prognosis when compared to acute myeloid leukemia with complex karyotype including del(5q). *Modern Pathology*, **2020**, 33, 566-575	9.8	0
60	Mathematical Modeling Provides Evidence for Niche Competition in Human AML and Serves as a Tool to Improve Risk Stratification. *Cancer Research*, **2020**, 80, 3983-3992	10.1	9
59	Structure-based design, synthesis and bioactivity evaluation of macrocyclic inhibitors of mutant isocitrate dehydrogenase 2 (IDH2) displaying activity in acute myeloid leukemia cells. *European Journal of Medicinal Chemistry*, **2020**, 203, 112491	6.8	2
58	Enasidenib for the treatment of relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase 2 mutation. *Expert Review of Precision Medicine and Drug Development*, **2020**, 5, 421-428	1.6	2
57	Mir142 loss unlocks IDH2-dependent leukemogenesis through antagonistic regulation of HOX genes. *Scientific Reports*, **2020**, 10, 19390	4.9	4
56	Ivosidenib for the treatment of relapsed or refractory acute myeloid leukemia with an IDH1 mutation. *Expert Review of Precision Medicine and Drug Development*, **2020**, 5, 429-438	1.6	1
55	Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes and in Acute Myeloid Leukemias. *Cancers*, **2020**, 12,	6.6	4

54	Acute Myeloid Leukemia: From Biology to Clinical Practices Through Development and Pre-Clinical Therapeutics. *Frontiers in Oncology*, **2020**, 10, 599933	5.3	4
53	IDH-Mutant Gliomas. **2020**,		3
52	Specific patterns of H3K79 methylation influence genetic interaction of oncogenes in AML. *Blood Advances*, **2020**, 4, 3109-3122	7.8	1
51	Dnmt3a loss and Idh2 neomorphic mutations mutually potentiate malignant hematopoiesis. *Blood*, **2020**, 135, 845-856	2.2	17
50	Identification of a selective inhibitor of IDH2/R140Q enzyme that induces cellular differentiation in leukemia cells. *Cell Communication and Signaling*, **2020**, 18, 55	7.5	4
49	Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes. *Internal Medicine*, **2021**, 60, 15-23	1.1	1
48	Epigenetic modifiers in normal and aberrent erythropoeisis. *Seminars in Hematology*, **2021**, 58, 15-26	4	1
47	Non-genetic heterogeneity, altered cell fate and differentiation therapy. *EMBO Molecular Medicine*, **2021**, 13, e12670	12	7
46	IDH1/IDH2 Inhibition in Acute Myeloid Leukemia. *Frontiers in Oncology*, **2021**, 11, 639387	5.3	11
45	Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia. *Journal of Experimental Medicine*, **2021**, 218,	16.6	10
44	Genome-wide analysis of focal DNA hypermethylation in IDH-mutant AML samples.		
43	Biological Roles and Therapeutic Applications of IDH2 Mutations in Human Cancer. *Frontiers in Oncology*, **2021**, 11, 644857	5.3	0
42	Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards. *ESMO Open*, **2021**, 6, 100040	6	7
41	Mitochondrial metabolism as a target for acute myeloid leukemia treatment. *Cancer & Metabolism*, **2021**, 9, 17	5.4	10
40	Hypoxia-Driven Oncometabolite L-2HG Maintains Stemness-Differentiation Balance and Facilitates Immune Evasion in Pancreatic Cancer. *Cancer Research*, **2021**, 81, 4001-4013	10.1	2
39	IDH2 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in multiple myeloma. *Oncogene*, **2021**, 40, 5393-5402	9.2	1
38	Mutations in Glioma: Double-Edged Sword in Clinical Applications?. *Biomedicines*, **2021**, 9,	4.8	4
37	Mutant Cooperates with a Fusion to Induce Early Immature Thymocyte Precursor ALL. *Cancer Research*, **2021**, 81, 5033-5046	10.1	1

36	Immunometabolism: A 'Hot' Switch for 'Cold' Pediatric Solid Tumors. *Trends in Cancer*, **2021**, 7, 751-777	12.5	1
35	MAIT cells numbers and frequencies in patients with acute myeloid leukemia at diagnosis: association with cytogenetic profile and gene mutations. *Cancer Immunology, Immunotherapy*, **2021**, 1	7.4	1
34	Using mathematical models to improve risk-scoring in acute myeloid leukemia. *Chaos*, **2020**, 30, 123150	3.3	1
33	Clinicopathologic Characterization of Hypocellular Acute Myeloid Leukemia (AML) Showed Fewer Genetic Abnormalities Involving Cell Proliferation and NPM1 When Compared With Nonhypocellular AML. *American Journal of Clinical Pathology*, **2021**, 155, 446-454	1.9	1
32	JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition. *Journal of Clinical Investigation*, **2018**, 128, 789-804	15.9	47
31	Angioimmunoblastic T cell lymphoma: novel molecular insights by mutation profiling. *Oncotarget*, **2017**, 8, 17763-17770	3.3	29
30	Novel Antigen Targets for Immunotherapy of Acute Myeloid Leukemia. *Current Drug Targets*, **2017**, 18, 296-303	3	12
29	Untangling the Metabolic Reprogramming in Brain Cancer: Discovering Key Molecular Players Using Mass Spectrometry. *Current Topics in Medicinal Chemistry*, **2019**, 19, 1521-1534	3	10
28	Enasidenib and ivosidenib in AML. *Minerva Medica*, **2020**, 111, 411-426	2.2	7
27	Genetically engineered mouse models for drug development and preclinical trials. *Biomolecules and Therapeutics*, **2014**, 22, 267-74	4.2	17
26	A systematic analysis of genetic interactions and their underlying biology in childhood cancer. *Communications Biology*, **2021**, 4, 1139	6.7	0
25	Oxidative Stress and Cancer Epigenomics. *Epigenetics and Human Health*, **2016**, 223-243		
24	Combinatory therapy targeting mitochondrial oxidative phosphorylation improves efficacy of IDH mutant inhibitors in acute myeloid leukemia.		
23	Hypoxia-driven oncometabolite L-2HG maintains stemness-differentiation balance and facilitates immune suppression in pancreatic cancer.		
22	Cancer Stem Cells: Metabolic Characterization for Targeted Cancer Therapy. *Frontiers in Oncology*, **2021**, 11, 756888	5.3	4
21	A comprehensive map of genetic interactions in childhood cancer reveals multiple underlying biological mechanisms.		
20	[Isocitrate dehydrogenase mutation in acute myeloid leukemia]. *Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi*, **2015**, 36, 82-4	0.4	
19	[Modification of DNA methylation in leukemia development]. *Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi*, **2016**, 37, 1003-1007	0.4	

18	Beyond Isocitrate Dehydrogenase Mutations: Emerging Mechanisms for the Accumulation of the Oncometabolite 2-Hydroxyglutarate.. *Chemical Research in Toxicology*, **2022**,	4	0
17	Exploring the Metabolic Landscape of AML: From Haematopoietic Stem Cells to Myeloblasts and Leukaemic Stem Cells.. *Frontiers in Oncology*, **2022**, 12, 807266	5.3	1
16	Focal disruption of DNA methylation dynamics at enhancers in IDH-mutant AML cells. *Leukemia*, **2021**,	10.7	2
15	Epigenetic enzyme mutations as mediators of anti-cancer drug resistance.. *Drug Resistance Updates*, **2022**, 61, 100821	23.2	2
14	Inhibition of mutant IDH1 promotes cycling of acute myeloid leukemia stem cells.		
13	Mouse Models of Frequently Mutated Genes in Acute Myeloid Leukemia.. *Cancers*, **2021**, 13,	6.6	0
12	Table_1.pdf. **2019**,		
11	Gliomas: Genetic alterations, mechanisms of metastasis, recurrence, drug resistance, and recent trends in molecular therapeutic options.. *Biochemical Pharmacology*, **2022**, 115090	6	0
10	IDH mutation and cancer stem cell. *Essays in Biochemistry*,	7.6	1
9	2-Hydroxyglutarate in Acute Myeloid Leukemia: A Journey from Pathogenesis to Therapies. *Biomedicines*, **2022**, 10, 1359	4.8	0
8	IDH2: A novel biomarker for environmental exposure in blood circulatory system disorders (Review). *Oncology Letters*, **2022**, 24,	2.6	0
7	Inhibition of mutant IDH1 promotes cycling of acute myeloid leukemia stem cells. **2022**, 40, 111182		0
6	Role of TET dioxygenases in the regulation of both normal and pathological hematopoiesis. **2022**, 41,		0
5	Differentiation Therapy. 1-19		0
4	Inhibition of Lonp1 induces mitochondrial remodeling and autophagy suppression in cervical cancer cells. **2023**, 125, 151986		1
3	Measurable Residual Disease Monitoring by Locked Nucleic Acid Quantitative Real-Time PCR Assay for IDH1/2 Mutation in Adult AML. **2022**, 14, 6205		1
2	Transgenic IDH2R172K and IDH2R140Q zebrafish models recapitulated features of human acute myeloid leukemia. **2023**, 42, 1272-1281		0
1	Single-center, observational study of AML/MDS-EB with IDH1/2 mutations: genetic profile, immunophenotypes, mutational kinetics and outcomes. **2023**, 28,		0